{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-26-006176","form_type":"8-K","ticker":"IRD","cik":"0001228627","company_name":"Opus Genetics, Inc.","filed_at":"2026-02-19T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.667059+00:00","generated_at":"2026-05-16T01:39:42.236966+00:00","sec_items":["1.01","2.02","3.02","5.03","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Opus Genetics raises $25M via Series B convertible preferred; pro forma cash $70M","bullets":["Closed private placement of 7,374,632 shares of Series B Non-Voting Convertible Preferred at $3.39/share for $25M.","Proceeds to advance gene therapy clinical programs, working capital, and general corporate purposes.","Preliminary cash balance $45M as of Dec 31, 2025; pro forma $70M after private placement proceeds.","Conversion to common stock requires stockholder approval at 2026 annual meeting; filing of Certificate of Designation.","Company entered into Registration Rights Agreement to register resale of conversion shares by April 19, 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-26-006176","json":"https://secwatch.observer/filing/0001140361-26-006176.json","markdown":"https://secwatch.observer/filing/0001140361-26-006176.md","text":"https://secwatch.observer/filing/0001140361-26-006176.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1228627/000114036126006176/0001140361-26-006176-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1228627/000114036126006176/ef20066083_form8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T01:39:42.236966+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"90ebd0cdcbf2ed62918081d875bf7ceffd4ba8ef","claim":"Opus Genetics, Inc. entered into Registration Rights Agreement with the Purchasers valued at Company will register the resale of shares of Common Stock issuable upon conversion of Series B Pref (effective 2026-02-18).","evidence_excerpt":"In connection with the Private Placement, the Company also entered into a Registration Rights Agreement, dated February 18, 2026 (the “Registration Rights Agreement”), with the Purchasers, which provides that the Company will register the resale of the shares of Common Stock issuable upon conversion of the Series B Preferred Stock.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1228627/000114036126006176/0001140361-26-006176-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"the Purchasers"},{"label":"Value","value":"Company will register the resale of shares of Common Stock issuable upon conversion of Series B Pref"},{"label":"Effective","value":"2026-02-18"}],"fact_type":"material_agreement"},{"claim_id":"f09501dd7eba434ca293a61d5ce4bf7a4d7ea13c","claim":"Opus Genetics, Inc. entered into Securities Purchase Agreement with certain purchasers valued at Aggregate purchase price of approximately $25.0 million for 7,374,632 shares of Series B Non-Voting (effective 2026-02-13).","evidence_excerpt":"On February 13, 2026, Opus Genetics, Inc. (the “Company”) entered into a securities purchase agreement (the “Securities Purchase Agreement”) with certain purchasers (the “Purchasers”) for a private placement (the “Private Placement”) of an aggregate of 7,374,632 shares of its Series B Non-Voting Convertible Preferred Stock, par value $0.0001 per share (the “Series B Preferred Stock”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1228627/000114036126006176/0001140361-26-006176-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"certain purchasers"},{"label":"Value","value":"Aggregate purchase price of approximately $25.0 million for 7,374,632 shares of Series B Non-Voting"},{"label":"Effective","value":"2026-02-13"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}